Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NVE Ephedra AERs Total 40; Yellow Jacket Distribution Halted

This article was originally published in The Tan Sheet

Executive Summary

NVE Pharmaceuticals has received only 40 adverse event reports related to its ephedra-containing dietary supplements, the firm tells Sen. Richard Durbin (D-Ill.) in an Oct. 21 letter

You may also be interested in...



NVE Offers Ephedra Study Funds; Metabolife Backs Mandatory Health Reports

NVE Pharmaceuticals will provide funding for "NIH or another appropriate government body to independently study the long-term safety of ephedra," the Newton, N.J.-based firm's President Robert Occhifinto testified at a July 23 Capitol Hill hearing

NVE Offers Ephedra Study Funds; Metabolife Backs Mandatory Health Reports

NVE Pharmaceuticals will provide funding for "NIH or another appropriate government body to independently study the long-term safety of ephedra," the Newton, N.J.-based firm's President Robert Occhifinto testified at a July 23 Capitol Hill hearing

NVE Offers Ephedra Study Funds; Metabolife Backs Mandatory Health Reports

NVE Pharmaceuticals will provide funding for "NIH or another appropriate government body to independently study the long-term safety of ephedra," the Newton, N.J.-based firm's President Robert Occhifinto testified at a July 23 Capitol Hill hearing

Related Content

Topics

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel